HomeNewsFocus on Haemostasis > COVID-19 & thrombotic disorders - Selected papers of interest - Guidances & Recommendations

COVID-19 & thrombotic disorders - Selected papers of interest - Guidances & Recommendations

Back to list

Stago has listed articles and publications related to the current COVID-19 infection and focusing on thrombosis and haemostasis issues.

In this section, guidance and recommendations published by national and international societies are addressed.

This page is updated regularly once new information is published.

 

In a separate section, Opens external link in current window“Research Publications”, all published scientific content of interest is collected.

 

GUIDANCES & RECOMMENDATIONS

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up


Source: Journal of the American College of Cardiology April 2020. DOI: 10.1016/j.jacc.2020.04.031
http://www.onlinejacc.org/content/early/2020/04/15/j.jacc.2020.04.031

The JACC Journals and the ACC worked to provide COVID-19 clinical guidance for global cardiovascular clinicians. Herein, authors have reviewed the current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexisting thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.
This publication is endorsed by the International Society on Thrombosis and Haemostasis (ISTH), the North American Thrombosis Forum (NATF), the European Society of Vascular Medicine (ESVM), and the International Union of Angiology (IUA). Supported by the ESC Working Group on the Pulmonary Circulation and Right Ventricular Function
A Commentary, recently published by SC Cannegieter and FA Klok in RPTH, address the clinical guidance and research priorities of JACC guidance.

See more at: https://onlinelibrary.wiley.com/doi/10.1002/rth2.12350

 

ISTH interim guidance on recognition and management of coagulopathy in COVID-19.

Source: Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. J Thromb Haemost. 2020 Mar 25; doi: 10.1111/jth.14810
http://doi.wiley.com/10.1111/jth.14810

The ISTH interim guidance recommends measuring D-dimer, prothrombin time and platelet count in all patients suspected of COVID-19 infection, in order to stratify risk of developing coagulopathy and to help in management.
An algorithm based on simple coagulation tests is proposed, including measurement of fibrinogen which may help to assess disseminated intravascular coagulation (DIC) in these patients. Finally, low molecular weight heparin (LMWH) treatment may be used in some COVID-19 patients.

Additionally to the guidance, two letters from same panel of authors provide more information and highlight specific topics:

Type and dose of heparin in COVID-19. Thachil J, Tang N, Gando S et al. J Throm Haemost 2020.
https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14870

Laboratory haemostasis monitoring in COVID-19. Thachil J, Tang N, Gando S et al. J Throm Haemost 2020.
https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14866


Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19

Source: Song JC, Wang G, Zhang W, et al. Military Medical Research (2020) 7:19. DOI: 10.1186/s40779-020-00247-7
https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-020-00247-7

This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.

 

Detailed recommendations for interactions with experimental COVID-19 therapies

Source: University of Liverpool.

In the course of COVID-19 infection management, a large number of patients are receiving off-label and compassionate use therapies such as chloroquine, hydroxychloroquine, azithromycin, lopinavir-ritonavir, favipiravir, remdesivir, ribavirin, interferon beta. However, many of these experimental therapies may be subject to potential drug-drug interaction.
The University of Liverpool has provided detailed recommendation to prevent potential drug-drug interactions in patients receiving these experimental drugs.
A section dedicated to anticoagulant, antiplatelet and fibrinolytic therapies highlights caution about DOACs, VKAs and anti-PY12 agents. Of note, dose adjustments were suggested for patients receiving DOACs.

View more at : https://www.covid19-druginteractions.org/


Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19.

Source: Hunt B, Retter A, McClintock Cl. Thromb UK [Internet]. 2020 Mar [cited 2020 Apr 4];
https://thrombosisuk.org/covid-19-thrombosis.php

This guidance from Thrombosis UK, authored by internationally recognized experts, helps with information to manage thrombotic risk, coagulopathy, and DIC in patients with COVID-19. This is a living guidance document that will be updated weekly.



The DIC score is of prognostic value in COVID-19 pneumonia.

Source: BSH Haemostasis and Thrombosis Task Force. 2020 Mar 18 [cited 2020 Apr 4];
https://b-s-h.org.uk/media/18151/dic-score-in-covid-19-pneumonia_19-03-2020.pdf

The British Society on Haematology published guidance established using data published by haematologists from Wuhan, China. This document indicates abnormal coagulation parameters can be a useful predictor of prognosis in pneumonia due to COVID-19.

 

Disclaimer: 
The above information is presented as scientific literature from the above publications, which, through their editorial boards consisting of independent reviewers with expertise in the subject of the article, have been made available electronically.  Please see the original journal article for further information on how to access the content, as well as to review any relevant conflicts or biases for all authors, contributors, or editors associated with the journal or organization.
Some of the uses described of the manufacturer’s product have not been cleared by the FDA, or by your local agency. Please refer to
https://www.stago.com/products-services/instructions-for-use/ for the current product labeling in alignment with the most recent FDA clearances for these products.

Top